E
EDWARDS LIFESCIENCES CORP
NYSE: EW (Edwards Lifesciences Corporatio)
Last update: 1 hour ago84.08
0.69 (0.83%)
| Previous Close | 83.39 |
| Open | 82.55 |
| Volume | 2,283,543 |
| Avg. Volume (3M) | 4,595,640 |
| Market Cap | 48,791,625,728 |
| Price / Earnings (TTM) | 36.88 |
| Price / Earnings (Forward) | 27.86 |
| Price / Sales | 7.97 |
| Price / Book | 4.27 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | 75.71% |
| Operating Margin (TTM) | 29.01% |
| Diluted EPS (TTM) | 2.42 |
| Quarterly Revenue Growth (YOY) | 6.20% |
| Quarterly Earnings Growth (YOY) | 1.70% |
| Total Debt/Equity (MRQ) | 6.86% |
| Current Ratio (MRQ) | 4.45 |
| Operating Cash Flow (TTM) | 876.20 M |
| Levered Free Cash Flow (TTM) | 1.45 B |
| Return on Assets (TTM) | 8.42% |
| Return on Equity (TTM) | 16.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Edwards Lifesciences Corporatio | Bullish | Bullish |
AIStockmoo Score
0.1
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -4.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | 0.13 |
|
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.91% |
| % Held by Institutions | 89.29% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Jennison Associates Llc | 30 Sep 2025 | 13,958,774 |
| Citadel Advisors Llc | 30 Jun 2025 | 12,731,291 |
| Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt | 30 Jun 2025 | 9,129,357 |
| Ninety One Uk Ltd | 30 Sep 2025 | 7,908,572 |
| Brown Advisory Inc | 30 Jun 2025 | 7,312,494 |
| Marshall Wace, Llp | 30 Jun 2025 | 6,895,579 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 104.00 (Goldman Sachs, 23.69%) | Buy |
| Median | 95.00 (12.99%) | |
| Low | 84.00 (Canaccord Genuity, -0.10%) | Hold |
| Average | 94.83 (12.79%) | |
| Total | 9 Buy, 3 Hold | |
| Avg. Price @ Call | 82.57 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 03 Nov 2025 | 84.00 (-0.10%) | Hold | 83.07 |
| Truist Securities | 03 Nov 2025 | 90.00 (7.04%) | Hold | 83.07 |
| 28 Oct 2025 | 87.00 (3.47%) | Hold | 82.19 | |
| Barclays | 31 Oct 2025 | 99.00 (17.75%) | Buy | 82.45 |
| Citigroup | 31 Oct 2025 | 96.00 (14.18%) | Buy | 82.45 |
| Evercore ISI Group | 31 Oct 2025 | 92.00 (9.42%) | Buy | 82.45 |
| 07 Oct 2025 | 88.00 (4.66%) | Buy | 76.72 | |
| Goldman Sachs | 31 Oct 2025 | 104.00 (23.69%) | Buy | 82.45 |
| JP Morgan | 31 Oct 2025 | 90.00 (7.04%) | Hold | 82.45 |
| Mizuho | 31 Oct 2025 | 100.00 (18.93%) | Buy | 82.45 |
| Piper Sandler | 31 Oct 2025 | 95.00 (12.99%) | Buy | 82.45 |
| RBC Capital | 31 Oct 2025 | 95.00 (12.99%) | Buy | 82.45 |
| Stifel | 31 Oct 2025 | 95.00 (12.99%) | Buy | 82.45 |
| 22 Sep 2025 | 85.00 (1.09%) | Buy | 73.75 | |
| Jefferies | 29 Oct 2025 | 98.00 (16.56%) | Buy | 82.69 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Nov 2025 | Announcement | Edwards Champions American Heart Association Initiative to Reduce Deaths, Improve Care for Patients With Heart Valve Disease |
| 30 Oct 2025 | Announcement | Edwards Lifesciences Announces CFO Transition Plan |
| 30 Oct 2025 | Announcement | Edwards Lifesciences Reports Third Quarter Results |
| 27 Oct 2025 | Announcement | Successful Patient Outcomes Demonstrated With Edwards’ SAPIEN M3 and EVOQUE Systems, New Data Presented at TCT 2025 |
| 27 Oct 2025 | Announcement | Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025 |
| 23 Oct 2025 | Announcement | Edwards Lifesciences to Host Earnings Conference Call on October 30, 2025 |
| 29 Aug 2025 | Announcement | Updated ESC/EACTS Guidelines Mark Advancement in Structural Heart Disease Care |
| 19 Aug 2025 | Announcement | Edwards Lifesciences Announces $500 Million Accelerated Share Repurchase |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |